Utilization of Genomic Signatures to Identify Phenotype-Specific Drugs

Open Access

Peer-reviewed

Research Article

Seiichi Mori,

Current address: Cancer Science Institute of Singapore, Genomic Oncology Programme, National University of Singapore, Singapore, Singapore

Affiliation Duke Institute for Genome Sciences & Policy, Duke University Medical Center, Durham, North Carolina, United States of America
⨯
Jeffrey T. Chang,

Affiliation Duke Institute for Genome Sciences & Policy, Duke University Medical Center, Durham, North Carolina, United States of America
⨯
Eran R. Andrechek,

Affiliation Duke Institute for Genome Sciences & Policy, Duke University Medical Center, Durham, North Carolina, United States of America
⨯
Anil Potti,

Affiliation Duke Institute for Genome Sciences & Policy, Duke University Medical Center, Durham, North Carolina, United States of America
⨯
Joseph R. Nevins

* E-mail: nevin001@mc.duke.edu

Affiliation Duke Institute for Genome Sciences & Policy, Duke University Medical Center, Durham, North Carolina, United States of America
⨯

Reader Comments (0)

Breast cancer
Is the Subject Area "Breast cancer" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Drug screening
Is the Subject Area "Drug screening" applicable to this article?

Thanks for your feedback.
Phenotypes
Is the Subject Area "Phenotypes" applicable to this article?

Thanks for your feedback.
Drug research and development
Is the Subject Area "Drug research and development" applicable to this article?

Thanks for your feedback.
Gene expression
Is the Subject Area "Gene expression" applicable to this article?

Thanks for your feedback.
Estrogens
Is the Subject Area "Estrogens" applicable to this article?

Thanks for your feedback.
Testicular cancer
Is the Subject Area "Testicular cancer" applicable to this article?

Thanks for your feedback.